Patent ID: 8663634

Claim:
A method of treating an autoimmune disorder or ameliorating the symptoms thereof in a patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of an anti-CD3 antibody that has at least 50% reduced binding to at least one FcγR than an antibody with a wild type Fc domain, wherein said administration results in minimal toxicity; wherein said treatment comprises a dosage regimen comprising doses of increasing amounts of said antibody on at least the initial 4 days of said dosage regimen; wherein the dose on day 1 is 1.6 μg/kg, the dose on day 2 is 3.2 μg/kg, the dose on day 3 is 6.5 μg/kg, the dose on day 4 is 13 μg/kg, and the dose on any subsequent days is 26 μg/kg; wherein said autoimmune disorder is type 1 diabetes; and wherein said patient is in the early stages of disease when about 80% of β-cells have been destroyed.